Navigation Links
ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO

repeated). Using these dosing regimens, 64% of rapid and intermediate acetylators and 77% of slow acetylators showed no dose-limiting drug toxicities or dose-delay/holds during treatment.

-- In a population of heavily pretreated patients who were refractory to multiple existing therapies and who had advanced tumors, there was evidence of antitumor activity in a range of tumor types. Three prostate cancers showed a decline in prostate specific antigen (PSA), with one of these achieving a partial response. Two patients with ovarian cancer achieved stable disease accompanied by a decline in the ovarian cancer biomarker CA125. One patient with gastrointestinal stromal tumor (GIST) demonstrated stable disease which was sustained over 18 monthly cycles of amonafide.

Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex said that the results were a significant step in the development of personalized medicines. "The data that Dr Kuhn presented today show very clearly that we now understand the effect of genotype on amonafide metabolism, and that we can dose patients to minimize the side effects of therapy. We are encouraged by the signs of anticancer activity across a range of tumor types in patients who had failed multiple prior therapies, and look forward to progressing Quinamed into further development for indications where the clinical need and commercial potential is greatest."

Quinamed(R) is a registered trademark of ChemGenex Pharmaceuticals Limited.

About ChemGenex Pharmaceuticals Limited (www.chemgenex.com)

ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes and obesity. ChemGenex harnesses the power of genomics for target discovery and validation, and in clinical trials to develop more individualized therapeutic outcomes. ChemGenex's lead compound, Ceflatonin(R), is currently in phase
'"/>




Page: 1 2 3 4

Related medicine technology :

1. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:10/16/2014)... Calif., Oct. 16, 2014  Cepheid (Nasdaq: ... of 2014 of $115.2 million, representing growth of 15% ... Net loss in the third quarter of 2014 was ... net loss of $(1.4) million, or $(0.02) per share, ... Excluding stock-based compensation expense, amortization of debt discount and ...
(Date:10/16/2014)... -- Eight finalists, all representing outstanding innovation in pediatric ... for a chance to compete for one of two ... Second Annual Pediatric Surgical Innovation Symposium hosted by ... 24, 2014. Selected from a competitive field ... internationally, the finalists are: , Creative ...
(Date:10/16/2014)... 16, 2014 Curtis & Coulter LLC, a ... away from hosting their co-located Bioequivalence: Intersection Between ... Formulation Innovations Summit taking place on November 5-6 ... November,s events are specifically designed ... the bioequivalence testing process, as well as optimizing formulation ...
Breaking Medicine Technology:Cepheid Reports 2014 Third Quarter Results 2Cepheid Reports 2014 Third Quarter Results 3Cepheid Reports 2014 Third Quarter Results 4Cepheid Reports 2014 Third Quarter Results 5Cepheid Reports 2014 Third Quarter Results 6Cepheid Reports 2014 Third Quarter Results 7Cepheid Reports 2014 Third Quarter Results 8Cepheid Reports 2014 Third Quarter Results 9Cepheid Reports 2014 Third Quarter Results 10Cepheid Reports 2014 Third Quarter Results 11Cepheid Reports 2014 Third Quarter Results 12Cepheid Reports 2014 Third Quarter Results 13Cepheid Reports 2014 Third Quarter Results 14Cepheid Reports 2014 Third Quarter Results 15Cepheid Reports 2014 Third Quarter Results 16Cepheid Reports 2014 Third Quarter Results 17Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2
... (OTC: IDTA) CEO Yaacov Shoham today announced the following order. ... sales in many new markets, including Australia-a most important market ... order for 2000 detectors from the Australian representative GK ... the past several months we have been in continuous contact ...
... 13, 2011 Quest Diagnostics Incorporated (NYSE: DGX ... services, announced today that it will report third quarter 2011 ... will hold its quarterly conference call with investors to discuss ... The public may access the conference call through ...
Cached Medicine Technology:International Drug & Explosives Detection Company IDenta Corp. Receives Order From Australia 2Quest Diagnostics to Release Third Quarter 2011 Financial Results 2
(Date:10/20/2014)... Viejo, California (PRWEB) October 20, 2014 Final ... announced the release of the Citrus theme for FCPX ... I would use to describe the Citrus theme” Says Christina ... so easy to look so professional.” , Citrus comes with ... Included with the template are: four transitions for added style, ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal ... throughout the greater Phoenix area and across Arizona reports ... to catastrophic automobile accidents. Statistics have indicated a steady ... Arizona. As such, Hastings and Hastings has seen a ... those who have been injured through no fault of ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular ... of bamboo deckings . Moreover, the company has ... are now available at deeply discounted rates. , ... to overstate the significance of online business nowadays. Thus, ... The company’s workers are striving to deliver both value ...
Breaking Medicine News(10 mins):Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... Back Chronic Disease,Initiatives, WASHINGTON, Oct. 20 ... many Americans are forgoing basic,medical care in the ... fight against chronic disease and support for care ... sense in tough economic times,--dining out less often ...
... chances of survival, study found , , MONDAY, Oct. 20 (HealthDay ... lymphoma increases if one is poor but decreases if the ... published in the Dec. 1 issue of Cancer , ... that blacks tend to have a higher risk of death ...
... LITTLE ROCK, Ark., Oct. 20 Heifer International, ... perfect,holiday gift alternative for the green-minded client, the ... for tighter gift budgets.,Heifer focuses on doing one ... 2 billion people living on less than $2 ...
... to Offer "Safe and Sober Free Cab Ride Home" , ... Alameda, ... will be adding Halloween to its list of holidays for the Safe ... up with Veterans Cab and Yellow Cab in Alameda and Luxor Cab ...
... member of PPI class for treatment for GERD and Erosive ... ... Company,Limited ("Takeda") today announced that Takeda Global Research and,Development Center, Inc., a ... Drug Administration (FDA) that,the agency will not be able to complete its ...
... Hydrate and Soothe Young Throats, FARMINGDALE, N.Y., ... approaches, Integrated Beverage Group, Ltd. (IBG), a manufacturer,of ... newest,product -- Children,s Throat Cooler(R). This non-medicated ready-to-freeze,liquid ... wish to choose a 100%,drug free product to ...
Cached Medicine News:Health News:Nation's Economic Downturn Threatens Continuity of Care for Chronic Conditions 2Health News:Heifer International: The Greener Good for Holiday Giving 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 3Health News:FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 3
... OcuLight OR (532 nm) is the ... The OcuLight family is widely,accepted for ... portability and it makes,up the worlds ... ,The OcuLight OR laser was specifically,designed ...
...
...
...
Medicine Products: